SecBot SecBot
8-K ·Filed Apr 27, 2026

ERAS

Erasca, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001193125-26-182137
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The strong preliminary efficacy and safety signal for ERAS-0015 positions it as a potential best-in-class pan-RAS inhibitor, significantly de-risking the program. Traders should watch for next data milestones (BOREALIS-1 2H 2026, AURORAS-1 expansion 1H 2027) and any partnership/licensing interest. The stock likely re-rates higher on this data.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.90
T+0 close · Apr 27, 2026 · via day close
Latest settled
+95.35%
T+60 · $19.34
Vs SPY
+91.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $9.90entry
  2. T+1 · 7mo ago −6.41%α −6.40% · $9.27
  3. T+5 · 7mo ago +2.42%α +0.73% · $10.14
  4. T+20 · 6mo ago +16.16%α +10.69% · $11.50
  5. T+60 · 4mo ago +95.35%α +91.36% · $19.34
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Erasca announced positive preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015, showing robust monotherapy response rates in KRAS G12X NSCLC (62% uORR8wk at PADs) and PDAC (40% uORR14wk) that exceeded comparator RMC-6236 by 24 and 11 percentage points, respectively. The data also demonstrated favorable safety with no DLTs and durable responses, supporting advancement into expansion cohorts ahead of schedule.

Key Facts

  • ERAS-0015 achieved 62% uORR8wk at PADs in 2L+ KRAS G12X NSCLC (N=37), exceeding comparator RMC-6236 by 24 percentage points.
  • In PDAC, 40% uORR14wk at PADs (N=20) exceeded comparator by 11 percentage points.
  • No DLTs observed; mostly low-grade AEs with no discontinuations due to TRAEs.
  • Monotherapy RDEs set at 24 mg and 32 mg QD; combination dose escalation with panitumumab initiated.
  • Upcoming catalysts: AURORAS-1 expansion/combination data 1H 2027; BOREALIS-1 Phase 1 data 2H 2026.

Financial Impact

No financial figures provided; the data supports pipeline value but does not change near-term financials.

Risk Factors

  • Preliminary data may not replicate in larger Phase 2/3 trials.
  • Cross-study comparisons with RMC-6236 are not head-to-head and may be confounded by trial design differences.
  • Competition from other RAS inhibitors (Revolution Medicines, etc.) could limit commercial potential.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-182137
Document: 0001193125-26-182137-index-headers.html0001193125-26-182137
Document: 0001193125-26-182137-index.html0001193125-26-182137
Document: 0001193125-26-182137.txt0001193125-26-182137

Track record

26 reports on ERAS

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
  4. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
  6. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
  7. Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
  8. Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
  9. Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
  10. Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026